Pennant Reports Second Quarter 2025 Results

Pennant Reports Second Quarter 2025 Results Conference Call and Webcast scheduled for tomorrow, August 7, 2025 at 10:00 am MT GlobeNewswire August 06, 2025 EAGLE, Idaho, Aug. 06, 2025 (GLOBE NEWSWIRE) — The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today […]

Ormat Technologies Reports Second Quarter 2025 Financial Results

Ormat Technologies Reports Second Quarter 2025 Financial Results GlobeNewswire August 06, 2025 EXPANDED PORTFOLIO AND FAVORABLE OBBB POLICY SUPPORT LONG TERM GROWTH TARGETS HIGHLIGHTS NET INCOME AND ADJUSTED EBITDA GROWTH OF 26.1% AND 6.7%, RESPECTIVELY SUCCESSFUL COMPLETION OF 20MW BLUE MOUNTAIN GEOTHERMAL POWER PLANT ACQUISITION SECURED $300 MILLION IN FUNDING TO SUPPORT FUTURE DEVELOPMENT COMPANY

MediaAlpha Reaches Settlement with FTC

MediaAlpha Reaches Settlement with FTC GlobeNewswire August 06, 2025 LOS ANGELES, Aug. 06, 2025 (GLOBE NEWSWIRE) — MediaAlpha, Inc. (NYSE: MAX) (“MediaAlpha” or the “Company”) today announced that it has reached a settlement with the Federal Trade Commission (“FTC”) to fully resolve matters related to the previously disclosed FTC investigation focused primarily on the Company's

Oportun Achieves Third Straight Quarter of GAAP Profitability and Raises Full-Year 2025 Outlook

Oportun Achieves Third Straight Quarter of GAAP Profitability and Raises Full-Year 2025 Outlook GlobeNewswire August 06, 2025 GAAP Net income of $6.9 million, a $38 million year-over-year improvement GAAP EPS of $0.14, a $0.92 year-over-year improvement Adjusted EPS of $0.31, up 288% versus prior-year quarter Operating expenses down 13% year-over-year, driving continued margin expansion Raising

Cerence Announces Third Quarter Fiscal 2025 Results; Revenue and Profitability Exceed High End of Guidance

(NASDAQ:CRNC), Headlines Revenue of $62.2 million; Net cash provided by operating activities of $23.7M; Free cash flow of $16.1 million marks fifth consecutive positive quarter Company raises and narrows full fiscal year guidance for revenue, adjusted EBITDA and free cash flow Company continues to advance innovation and gain customer momentum for Cerence xUI, its hybrid

EverCommerce Announces Second Quarter 2025 Financial Results

EverCommerce Announces Second Quarter 2025 Financial Results GlobeNewswire August 06, 2025 DENVER, Aug. 06, 2025 (GLOBE NEWSWIRE) — EverCommerce Inc. (“EverCommerce” or the “Company”) (NASDAQ: EVCM), a leading service commerce platform, today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue from continuing operations of $148.0 million, an

American Coastal Insurance Corporation Reports Financial Results for Its Second Quarter Ended June 30, 2025

American Coastal Insurance Corporation Reports Financial Results for Its Second Quarter Ended June 30, 2025 GlobeNewswire August 06, 2025 Company to Host Quarterly Conference Call at 5:00 P.M. ET on August 6, 2025 The information in this press release should be read in conjunction with an earnings presentation that is available on the Company's website

Open Lending Reports Second Quarter 2025 Financial Results

(NasdaqGM:LPRO), AUSTIN, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) — Open Lending Corporation (Nasdaq: LPRO) (the “Company” or “Open Lending”), an industry trailblazer in lending enablement and risk analytics solutions for financial institutions, today reported financial results for its second quarter ended June 30, 2025. “I am pleased with our progress as the team executes against

SuRo Capital Corp. Reports Second Quarter 2025 Financial Results

SuRo Capital Corp. Reports Second Quarter 2025 Financial Results GlobeNewswire August 06, 2025 Ongoing Net Asset Value Growth Driven by AI-Focused Investments Net Asset Value of $9.18 Per Share as of June 30, 2025 NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) — SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS)

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

(NASDAQ:ASMB), – Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Further pharmacological assessment to be conducted in parallel with Phase 2 preparation – SOUTH SAN FRANCISCO, Calif., Aug. 06,

Scroll to Top